A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)